Re-infection following sustained virological response with a different hepatitis C virus genotype: implications for infection control policy

We report the case of a 45-year-old haemodialysis patient who achieved a sustained virological response (SVR) following pegylated interferon therapy for hepatitis C virus (HCV) genotype 2 infection. He was subsequently cohorted with other HCV-infected dialysis patients and became re-infected with HC...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Shaughnessy, Michelle M., O'Regan, John A., Murray, Frank E., Connell, Jeff A., Duffy, Margaret P., Francis, Veronica M., Dwyer, Sharon, Thornton, Lelia M., Conlon, Peter J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Clinical Cases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400513/
https://www.ncbi.nlm.nih.gov/pubmed/26069778
http://dx.doi.org/10.1093/ckj/sfs040
Descripción
Sumario:We report the case of a 45-year-old haemodialysis patient who achieved a sustained virological response (SVR) following pegylated interferon therapy for hepatitis C virus (HCV) genotype 2 infection. He was subsequently cohorted with other HCV-infected dialysis patients and became re-infected with HCV genotype 3a. Epidemiological and molecular investigations identified a highly viraemic HCV genotype 3a-infected dialysis patient as the likely source of this infection. This critical incident informed a revision to local and national infection control policy regarding the dialysis management of patients who achieve an SVR following anti-viral treatment.

Ejemplares similares